← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Melanotan II × PT-141 × 2 of 4 selected View comparison

Melanotan II

Cyclic melanocortin agonist

Remove
VS

PT-141

Cyclic melanocortin receptor agonist

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target Melanotan IIPT-141
✓ ✓

Pathway Map

This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.

Melanotan II → Broader melanocortin receptor agonism
PT-141 → Central melanocortin signalling associated with sexual-response research

What These Compounds Share

Shared direct targets (all selected compounds)
MELANOCORTIN
Shared research line

All selected compounds are catalogued under Enhance.

Shared pathway tags
Melanocortin

Key Differences

Melanotan II Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. Broader melanocortin receptor activity than Melanotan I.
PT-141 Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. A melanocortin-derived compound developed around central sexual-response signalling rather than primarily pigmentation.

Compound Detail

Melanotan II
What is it?
A lab-made peptide that broadly activates the body's pigmentation and appetite-signalling system.
What are people researching/using it for?
Studied for skin tanning/pigmentation.
Other uses being trialed
Sexual-response researchAppetite-related research
Worth knowing
Not MC1R-selective -- broader melanocortin receptor activity than Melanotan I. Early human trials were small (3-20 participants) and used the compound directly, not the more targeted derivative developed afterward (bremelanotide/PT-141).

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A cyclic α-MSH analogue with broader melanocortin receptor activity than Melanotan I.
Synthetic cyclic α-MSH analogue · Synthetic analogue
Also known as: MT-II
Primary Targets & Biological System
Melanocortin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A cyclic analogue of α-MSH that activates multiple melanocortin receptors rather than being selective for any single one -- unlike Melanotan I, which is predominantly MC1R-focused. This broader receptor activity is the mechanistic reason Melanotan II's research interest extends beyond pigmentation (MC1R's primary domain) into appetite and sexual-response research, since other melanocortin receptors in the family (such as MC4R) are more strongly linked to those functions.
Research Areas
PigmentationMelanocortin signallingSexual-response researchAppetite/CNS melanocortin biology
Research Profile
Human administration: Limited Preclinical: Available
Pharmacokinetics
Not displayed as a definitive value without a direct source.
Research Routes
Subcutaneous (early human research) (descriptive only — not administration or dosing guidance)
Key Differentiator
Broader melanocortin receptor activity than Melanotan I.
Considerations
Research Limitations
Not MC1R-selective -- broader melanocortin receptor activity than Melanotan I. Early human trials were small (3-20 participants) and used the compound directly, not the more targeted derivative developed afterward (bremelanotide/PT-141).
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Sexual response / erectile function
Two double-blind, placebo-controlled human crossover trials directly tested Melanotan II for this use: in one, 8 of 10 men with psychogenic erectile dysfunction developed clinically apparent erections; in a larger follow-up of 20 men with psychogenic or organic ED, 17 of 20 responded, and increased sexual desire was reported after 68% of Melanotan II doses versus 19% of placebo doses. This is genuine controlled human evidence directly for Melanotan II itself -- it was also the original research basis that led to the development of PT-141/bremelanotide as a more targeted follow-on compound, but Melanotan II has its own directly-studied human trial history, not merely a precursor role.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Melanotan II · A$54.95 A$69.95
Browse products →
View Research Sources (3) →
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study
Journal of Urology, 1998 · Human Human · 10 men with erectile dysfunction of no known organic cause · Not specified in this record -- see prescribing/trial documentation · PMID 9679884

Double-blind, placebo-controlled crossover, RigiScan-monitored over 6 hours. Clinically apparent erections in 8/10 men on Melanotan II. Mean tip-rigidity >80% duration: 38.0 min (MT-II) vs 3.0 min (placebo), P=0.0045.

Supports: experimental_research

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II
International Journal of Impotence Research, 2000 · Human Human · 20 men with psychogenic or organic erectile dysfunction · PMID 11035391

Double-blind, placebo-controlled crossover, RigiScan-monitored. Erection without sexual stimulation in 17/20 men (mean 41 min tip rigidity >80%). Increased sexual desire reported after 68% of MT-II doses vs 19% of placebo doses (P<0.01). Severe nausea in 12.9% at 0.025 mg/kg.

Supports: experimental_research

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
Life Sciences, 1996 · Human Human · 3 normal male volunteers · Not specified in this record · PMID 8637402

Single-blind, alternating-day, placebo-controlled Phase I safety/pigmentation study. Mild nausea and stretching/yawning correlating with spontaneous erections; increased pigmentation of face/upper body/buttock in 2 of 3 subjects. Recommended future Phase I dose: 0.025 mg/kg/day.

Supports: mechanism_summary, short_description

PT-141
What is it?
A lab-made peptide that acts on brain signalling related to sexual response.
What are people researching/using it for?
Approved and studied for sexual desire/arousal research.
Other uses being trialed
General central-nervous-system melanocortin research
Worth knowing
Mechanism is central (CNS melanocortin signalling), not a vascular mechanism analogous to PDE5 inhibitors. Regulatory PK data below apply specifically to bremelanotide -- only reliable if the compared material's chemical identity is equivalent to bremelanotide.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A melanocortin-derived compound developed around central sexual-response signalling rather than primarily pigmentation.
Cyclic heptapeptide · 7 amino acids · Synthetic analogue
Also known as: Bremelanotide
Primary Targets & Biological System
Central melanocortin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Bremelanotide activates melanocortin receptors in the central nervous system -- research has particularly implicated MC4R -- rather than acting on the vascular system the way PDE5 inhibitors (a different, more commonly known class of sexual-response compound) do. This central mechanism is why its effects are studied in relation to sexual desire/arousal pathways in the brain rather than blood flow to peripheral tissue, a meaningful distinction worth keeping separate from vascular-mechanism compounds when comparing research on sexual response.
Research Areas
Sexual response researchCNS melanocortin signalling
Research Profile
Human administration: Extensive Preclinical: Available
Pharmacokinetics
Approximately 2.7 hours
FDA prescribing information (Vyleesi/bremelanotide): median Tmax ~1 hour, terminal half-life ~2.7 hours, subcutaneous bioavailability ~100%, plasma protein binding ~21%.
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
A melanocortin-derived compound developed around central sexual-response signalling rather than primarily pigmentation.
Considerations
Research Limitations
Mechanism is central (CNS melanocortin signalling), not a vascular mechanism analogous to PDE5 inhibitors. Regulatory PK data below apply specifically to bremelanotide -- only reliable if the compared material's chemical identity is equivalent to bremelanotide.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Male sexual response
Bremelanotide's FDA approval (as Vyleesi) is specifically for hypoactive sexual desire disorder in premenopausal women; its central melanocortin mechanism has also been investigated in male sexual-response research, but this is outside its approved indication.
Appetite / obesity research
Because it shares the broader melanocortin pathway with appetite-related receptors, PT-141 has been studied in early-stage appetite research -- a secondary, less-characterised research direction relative to its sexual-response work.
Availability & Sources
Current Vital Edge Testing
Batch 2 · tested Oct 2026 · 99.979% purity, 10.06mg content Purity/ID report
Available As (Vital Edge Science)
PT-141 · A$54.95 A$69.95
Browse products →
View Research Sources (1) →
Vyleesi (bremelanotide) Prescribing Information
FDA Prescribing Information — Vyleesi · Regulatory document Human

Median Tmax ~1h, terminal half-life ~2.7h, SC bioavailability ~100%, protein binding ~21%. Applies to bremelanotide specifically.

Supports: human_half_life, research_routes

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.